Many of the University of Texas’s medical developments involve the use of synthetic materials to aid in treating patients. One patent application would protect a scaffold for tissue engineering that biodegrades and delivers treatment over time. Another application describes a system of using nanoparticles to stimulate hyperthermia to treat tumors. A third application discusses an improved bioadhesive for sealing tissues together. Other notable patent application filings pertain to improved systems of diagnosing and treating diseases that usually cause a poor prognosis in patients. One patent application deals with a system of analyzing gene expressions to determine a patient’s susceptibility to renal cell carcinoma. A final application we feature provides for a more effective course of treatment for most gastrointestinal tract infections.
The conjugates covered by this patent could enable less frequent and better tolerated dosing of one of the most widely used treatments worldwide for relapsing-remitting multiple sclerosis, interferon-beta-1b. The invention described in the European Patent relates to methods for the preparation of conjugates of poly(ethylene glycol), and derivatives thereof, with interferon-beta-1b. Compared to the corresponding unconjugated bioactive components, the conjugates of the invention have increased stability (i.e., longer shelf life and longer half-lives in vivo). In addition, compared to conjugates of the same bioactive component prepared with polymer chains that are attached randomly to solvent-accessible sites along the polypeptide chains, the conjugates of the invention have increased receptor-binding activity and increased potency.